This study is for a type of lung cancer called metastatic squamous non-small cell lung cancer (mNSCLC). "Metastatic" means the cancer has spread, and "squamous" is a type of cell in the lungs. The trial tests two treatments: rilvegostomig and pembrolizumab, both with chemotherapy. Chemotherapy is a treatment that uses strong medicine to kill cancer cells. The study wants to see which treatment works better and is safer for patients whose tumors have a protein called PD-L1. This protein helps cancer hide from the body's defense system.

Here are three key points:

• Participants will be randomly assigned to one of two groups to receive a treatment.
• The study will take place in multiple locations around the world and is estimated to last several months.
• Participants must meet specific health criteria, and compensation may be available.

People with certain health conditions, past treatments, or certain other cancers may not qualify. It's important to discuss with a doctor to see if joining is a good idea.